PDI client won’t renew $35 million deal

Share this article:
Contract sales firm PDI said a “large pharmaceutical company” client has decided not to renew a $35 million contract sales engagement with the firm. PDI said it had expected the one-year deal, which expires May 12, to be extended through the end of 2007. The loss of the deal, announced yesterday, is just the latest in a series of contract setbacks for PDI. In October, GlaxoSmithKline decided not to renew its 2007 sales agreement with PDI. That deal represented as much as $70 million in annual revenue for the contract sales firm. Also in October, Sanofi-Aventis ended a $20 million sales engagement with PDI. And in March 2006, AstraZeneca discontinued its fee-for-service agreements with PDI, after previously working with the firm for 12 years. That termination affected approximately 800 field representatives and impacted $65 to $70 million of PDI’s revenue. PDI CEO Michael Marquad called the latest setback “disappointing” in a statement, adding that it “underscores the importance of our strategy, which focuses on diversifying our revenue stream.” Marquad added that PDI would continue to be engaged in discussions with other large pharma companies for fee-for-service contracts, while exploring potential acquisition opportunities.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...